The antitrypanosomal drug melarsoprol competitively inhibits thiamin uptake in mouse neuroblastoma cells.
Melarsoprol is the main drug used for the treatment of late-stage sleeping sickness, although it causes severe side-effects such as encephalopathy and polyneuropathy leading to death in some patients. Recent data suggest that melarsoprol and its active metabolite melarsenoxide interfere with thiamin transport and metabolism in E. coli and yeast, but there are no data concerning their possible effects on thiamin metabolism in mammalian cells. We tested both drugs on thiamin transport in cultured mouse neuroblastoma cells using (14)C-labeled thiamin. Melarsoprol, competitively inhibits high-affinity thiamin transport in mouse neuroblastoma cells with a K(i) of 44 micromol/L. However, the active compound melarsenoxide has no inhibitory effect. This suggests that the side effects of melarsoprol treatment are unlikely to be due to inhibition of thiamin transport by melarsenoxide, its main metabolite in the brain.
Center for Cellular and Molecular Neurobiology, University of Liège, Liège, Belgium.
P
P
Szyniarowski
L
L
Bettendorff
M E
ME
Schweingruber
D000818:Animals; D045744:Cell Line, Tumor; D008549:Melarsoprol / Q000494:pharmacology*; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism*; D013831:Thiamine / Q000493:pharmacokinetics*; D014344:Trypanocidal Agents / Q000494:pharmacology*
D014344:Trypanocidal Agents; D013831:Thiamine; D008549:Melarsoprol